Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Surgical Pathology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Thyroid cancer incidence and mortality trends in the United States: 2000-2018.Thyroid. 2022; 32: 560-570
- Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.JAMA. 2017; 317: 1338-1348
- Controversies, consensus, and collaboration in the use of (131)i therapy in differentiated thyroid cancer: a joint statement from the american thyroid association, the european association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the european thyroid association.Thyroid. 2019; 29: 461-470
- Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.J Clin Endocrinol Metab. 2006; 91: 2892-2899
- Papillary thyroid carcinoma with high-grade features versus poorly differentiated thyroid carcinoma: an analysis of clinicopathologic and molecular features and outcome.Thyroid. 2021; 31: 933-940
- Outcomes in patients with poorly differentiated thyroid carcinoma.J Clin Endocrinol Metab. 2014; 99: 1245-1252
- Integrated genomic characterization of papillary thyroid carcinoma.Cell. 2014; 159: 676-690
- Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.PLoS Genet. 2016; 12: e1006239
- RET, NTRK, ALK, BRAF, and MET Fusions in a large cohort of pediatric papillary thyroid carcinomas.Thyroid. 2020; 30: 1771-1780
- Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident.Science. 2021; 372: eabg2538-eabg2725
- Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.Mod Pathol. 2020; 33: 2458-2472
- pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions.Oncologist. 2017; 22: 255-263
- NTRK-rearranged papillary thyroid carcinoma demonstrates frequent subtle nuclear features and indeterminate cytologic diagnoses.Cancer Cytopathol. 2022; 130: 136-143
- Characterization of thyroid cancer driven by known and novel ALK fusions.Endocr Relat Cancer. 2019; 26: 803-814
- Cytomorphologic features of NTRK-rearranged thyroid carcinoma.Cancer Cytopathol. 2020; 128: 812-827
- Fine-needle aspiration cytomorphology of papillary thyroid carcinoma with NTRK gene rearrangement from a case series with predominantly indeterminate cytology.Cancer Cytopathol. 2020; 128: 803-811
- NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.Cancer. 2016; 122: 1097-1107
- secretory carcinoma of the thyroid gland: report of a highly aggressive case clinically mimicking undifferentiated carcinoma and review of the literature.Head Neck Pathol. 2019; 13: 562-572
- Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.J Clin Invest. 2016; 126: 1052-1066
- Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers.Clin Cancer Res. 2018; 24: 3059-3068
- Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.Hum Mol Genet. 2015; 24: 2318-2329
- Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases.Histopathology. 2022; 80: 322-337
- The molecular landscape of hürthle cell thyroid cancer is associated with altered mitochondrial function-a comprehensive review.Cells. 2020; 9: 1570
- Integrated genomic analysis of hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes.Cancer Cell. 2018; 34: 256-270.e255
- Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in hürthle cell carcinoma.Cancer Cell. 2018; 34: 242-255.e245
- Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors.Proc Natl Acad Sci U S A. 2007; 104: 9001-9006
- Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds.Proc Natl Acad Sci U S A. 2019; 116: 2545-2550
- The KRAS-G12C inhibitor: activity and resistance.Cancer Gene Ther. 2022; 29: 875-878
- The landscape of kinase fusions in cancer.Nat Commun. 2014; 5: 4846
- Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.N Engl J Med. 2015; 372: 621-630
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.Lancet. 2014; 384: 319-328
- Advances in targeting RET-dependent cancers.Cancer Discov. 2020; 10: 498-505
- Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Lancet Oncol. 2016; 17: 1272-1282
- Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer.J Clin Oncol. 2018; 36: 7-13
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.Ann Oncol. 2022; 33: 406-415
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.Nature. 2010; 464: 427-430
- The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions.Front Microbiol. 2018; 9: 1806
- Acquired secondary RAS mutation in BRAF(V600E)-mutated thyroid cancer patients treated with BRAF inhibitors.Thyroid. 2020; 30: 1288-1296
- Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.N Engl J Med. 2013; 368: 623-632
- Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial.Thyroid. 2022; 32: 273-282
- Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.Endocrine. 2022; 76: 660-670
- Efficacy of selpercatinib in RET-altered thyroid cancers.N Engl J Med. 2020; 383: 825-835
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.Lancet Diabetes Endocrinol. 2021; 9: 491-501
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol. 2020; 21: 531-540
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.Lancet Oncol. 2018; 19: 705-714
- Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.Eur J Endocrinol. 2022; 186: 631-643
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.Lancet Oncol. 2020; 21: 271-282
- What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).Ann Oncol. 2016; 27: 920-926
- Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.N Engl J Med. 2018; 378: 731-739
- Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer.Cancer Discov. 2016; 6: 36-44
- Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.Ann Oncol. 2019; 30: 325-331
- clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib.J Natl Compr Canc Netw. 2021; 19: 478-482
- Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and resistant mutations.Mol Cancer Ther. 2021; 20: 2446-2456
- Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.World J Surg. 2014; 38: 1296-1305
- Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer: a case report and review of literature.World J Clin Oncol. 2020; 11: 495-503
- Remarkable response to ceritinib and brigatinib in an anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma previously treated with crizotinib.Thyroid. 2020; 30: 343-344
- Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma.J Clin Oncol. 2015; 33: e84-e87
- A novel ALK fusion in pediatric medullary thyroid carcinoma.Thyroid. 2019; 29: 1704-1707
- Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity.Clin Cancer Res. 2019; 25: 6662-6670
- Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data.Oncol Res Treat. 2015; 38: 291-298
- A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.Ann Oncol. 2013; 24: 3089-3094
- Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study.Clin Cancer Res. 2018; 24: 1546-1553
- Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II clinical trial.J Clin Endocrinol Metab. 2017; 102: 698-707
- Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.Cancer. 2006; 107: 2134-2142
- Medullary thyroid carcinoma: The third most common thyroid cancer reviewed.Oncol Lett. 2011; 2: 49-53
- Revised american thyroid association guidelines for the management of medullary thyroid carcinoma.Thyroid. 2015; 25: 567-610
- Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.Cancer Res. 2006; 66: 10741-10749
- Medullary thyroid carcinoma: recent advances including MicroRNA expression.Endocr Pathol. 2016; 27: 312-324
- Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course.Cancer. 2002; 94: 44-50
- Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.Br J Cancer. 2009; 100: 1777-1783
- RET fusion as a novel driver of medullary thyroid carcinoma.J Clin Endocrinol Metab. 2015; 100: 788-793
- Putative BRAF activating fusion in a medullary thyroid cancer.Cold Spring Harb Mol Case Stud. 2016; 2: a000729
- Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer.PLoS Genet. 2015; 11: e1005467
- Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.J Clin Oncol. 2012; 30: 134-141
- Cabozantinib in progressive medullary thyroid cancer.J Clin Oncol. 2013; 31: 3639-3646
- Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2021; 22: 1126-1138
- RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.J Thorac Oncol. 2020; 15: 541-549
- Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.Ann Oncol. 2021; 32: 261-268
- The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.J Clin Oncol. 2020; 38: 3616
- High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.J Clin Endocrinol Metab. 2011; 96: E863-E868
- COSMIC: the catalogue of somatic mutations in cancer.Nucleic Acids Res. 2019; 47: D941-D947
- RAS-targeted therapies: is the undruggable drugged?.Nat Rev Drug Discov. 2020; 19: 533-552
- Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.J Clin Endocrinol Metab. 2011; 96: 997-1005
- BRAF V600E mutation across multiple tumor types: correlation between DNA-based sequencing and mutation-specific immunohistochemistry.Appl Immunohistochem Mol Morphol. 2018; 26: 709-713
- BRAF V600E mutation-specific antibody: a review.Semin Diagn Pathol. 2015; 32: 400-408
- NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility.Histopathology. 2021; 79: 650-660
- Detecting N-RAS Q61R Mutated Thyroid Neoplasias by Immunohistochemistry.Endocr Pathol. 2017; 28: 71-74
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.Mod Pathol. 2020; 33: 38-46
- Detection of NTRK fusions: merits and limitations of current diagnostic platforms.Cancer Res. 2019; 79: 3163-3168
- Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer.Endocr Relat Cancer. 2015; 22: 55-63
- A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma.Am J Surg Pathol. 2015; 39: 652-659
- A performance comparison of commonly used assays to detect RET fusions.Clin Cancer Res. 2021; 27: 1316-1328
- Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.Hum Pathol. 2020; 106: 82-92
- Detection of NTRK1/3 rearrangements in papillary thyroid carcinoma using immunohistochemistry, fluorescent in situ hybridization, and next-generation sequencing.Endocr Pathol. 2020; 31: 348-358
- Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.Mod Pathol. 2018; 31: 791-808
- Clinical utility and performance of an ultrarapid multiplex RNA-based assay for detection of ALK, ROS1, RET, and NTRK1/2/3 rearrangements and MET exon 14 skipping alterations.J Mol Diagn. 2022; 24: 642-654
- 5'/3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer.J Exp Clin Cancer Res. 2018; 37: 68
- Clinical evaluation of the effectiveness of fusion-induced asymmetric transcription assay-based reverse transcription droplet digital PCR for ALK detection in formalin-fixed paraffin-embedded samples from lung cancer.Thorac Cancer. 2020; 11: 2252-2261
- A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.J Mol Diagn. 2014; 16: 229-243
- Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.Sci Rep. 2017; 7: 42259
- Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.J Pathol. 2009; 217: 707-715
- NTRK fusion-positive cancers and TRK inhibitor therapy.Nat Rev Clin Oncol. 2018; 15: 731-747
- american head and neck society endocrine surgery section and international thyroid oncology group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment.Head Neck. 2022; 44: 1277-1300
- Clinicopathologic features of mismatch repair-deficient anaplastic thyroid carcinomas.Thyroid. 2019; 29: 666-673
- Microsatellite instability occurs in a subset of follicular thyroid cancers.Thyroid. 2019; 29: 523-529
Further reading
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.Lancet Oncology. 2022; 23 (In this issue): 1261-1273https://doi.org/10.1016/S1470-2045(22)00541-1
Article info
Publication history
Published online: December 10, 2022
Footnotes
The author declares no conflict of interest.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
